Colorado Drug Rehab Menu

Alcohol and Drug Addiction

Drug Rehab Receptionist

Colorado Drug Rehab Cities:

Contact Colorado Drug Rehab, 888.781.7060, before you make a decision on a drug rehab center. Talk to a Counselor that has reviewed over 150 centers, on site, and can share his experiences and help you find the best program.

Click here to read more.

Alcohol and Drug Detox is the first step in getting your life back. Let us guide you in the proper, painless detox.

Click here for more details.

We have specifically chosen programs have had great success in curing the meth addiction and returning you to a sane existence without replacing the crystal meth with other drugs or pharmaceuticals.

Click here for more details.

Colorado Mountains

Colorado Drug Rehab Suboxone® Opiate Replacement



Thin Dotted line for Colorado Drug Rehab

Here is the reprint from an article from May 24, 2010 from Mediscape Medical News. Please read this lengthy article for the latest research on buprenorphine... also call and talk to our licensed counselors to understand how buprenorphine may or may not be right for you!

If you need to find a physician that can prescripe buprenorphine, follow this link: http://buprenorphine.samhsa.gov/bwns_locator/

Anytime that you find "research" showing that one form of opiate replacement therapy is ineffective, you have to ask yourself, "Who benefits from this research?" The methadone industry in the US is the most profitable form of treatment for opiate addiction. Opiate addiction includes, heroin, morphine, OxiContin®, Vicodin® or hydrocodone of any kind, or, basically, any kind of painkiller. Next to alcoholism, opiate addiction is American's number one form of substance abuse and addiction and there are huge profits being made at the methadone clinic level and NIDA and other government agencies are reporting that opiate replacement therapy is the only effective form of treatment. This is absolutely NOT TRUE, but it does support methadone commerce.

Buprenorphine has been used in Europe for many years before it was allowed to be used the U.S. Not because we have a better investigatory system for approving new medications, but because having buprenorphine in the US was going to cut into the profits of those in the methadone retail business; methadone clinics.

Please note that at about the same time that this research was presented, there is a company in the US that now has FDA permission to make a generic buprenorphine. Up until now, Subutex® or Suboxone®, both buprenorphine products, were manufactured by one company and were extremely expensive to that needed temporary withdrawal support.

This generic and lower cost buprenorphine leaves the methadone sellers anxious that they will lose clients to the buprenorphine sales. At present, if you take methadone for replacement therapy, you have to get it from a licensed methadone clinic. You can't go to the drug store with a prescription. However, if you take Subutex® or Suboxone® or the new generic buprenorphine, you can buy that at lower prices from the competitive pharmacies.

You do the math, but remember, when it comes to easy cures for addiction, BUYER BEWARE!

How Long Should You Wait Before Taking Suboxone® or Another Form of Bbuprenorphine?

Buprenorphine works as an antagonist to the opiate effects, so if you are taking other opiates, referred to as angonist opiates, you need to use precausion before you begin taking Suboxone®. If you take it too soon, it will precipitate withdrawals symptoms, meaning that it will kick you into worse cravings and withdrawal symptoms.

If you are seeing a doctor to get your Suboxone®, they will advice you of how long you should wait, but as a rule, you should follow the following times:

• Heroin – 12- 24 hours
• Percocet, Vicodin, or Oxycodone – 12-24 hours
• Crushed Oxycontin – 12 – 24 hours
• Oxycontin 24 hours +
• Methadone (must be at low dose) 36 hours (at least)

It is in your best interest to follow the advice and instructions of your doctor, and wait until you are truly in the early stages of withdrawal prior to taking a first dosage of Suboxone. After you take Suboxone under supervision in the doctor's office, you can expect to feel much better within a very short time.

There is a subjective test, the COWS Test, that you can perform to see when it is save to use buprenorphine. Find the COWS test at this site: http://www.naabt.org/documents/COWS_Induction_flow_sheet.pdf

There is tremendous dispute as to the benefits or deficits of buprenorphine replacement as a therapy. It is beneficial as an aid in deotxing from opiates, but as a replacement therapy, you should be aware that you will always have impairment with any opiate replacement therapy. The "neuroscience" tries to persuade you into believing that opiate addiction is a chemical imbalance within your brain. Granted, after prolong opiate use, your neuro-receptors are imbalanced, but supporting that imbalance with other opiate replacements hinders your chances of getting back to homeostasis or equilibrium, where you can again feel the love and joy of your life and that of others. Don't trust any replacement drug to bring you to that normal state that you were in before you ever took your first mind-altering drugs.

So... read this article and recognize that there is some truth to their discoveries. This is presented to on this website for your education only, not as a representation of Colorado Drug Rehab's philosophy.

May 24, 2010 (New Orleans, Louisiana) — In persons dependent on prescription opioids, tapering with buprenorphine during a 9-month period, whether initially or after a period of substantial improvement, led to nearly universal relapse in the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study, presented here at the American Psychiatric Association 2010 Annual Meeting.

"There has been virtually no research on the treatment of persons dependent on prescription opioids, in spite of the major increase in prescription opioid abuse and in the numbers of persons entering treatment for addiction to prescription opioids," said Roger D. Weiss, MD, professor of psychiatry at Harvard Medical School, Boston, and chief of the Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, Massachusetts.

The study, which is the largest treatment study ever conducted for prescription opioid dependence (POD), sought to answer several questions regarding the optimal length of pharmacotherapy, the value of intense counseling, and the role of chronic pain.

Specifically, the study asked whether adding individual drug counseling to buprenorphine-naloxone (a semisynthetic opioid and a partial agonist) plus standard medical management improves outcomes, what duration of buprenorphine is best for these patients, and whether presence or absence of current chronic pain influences outcomes.

"The trial was designed to help the physician manage patients who are dependent on opioids and want off the drugs but refuse treatment in a drug abuse treatment program," Dr. Weiss said.

The study enrolled 653 persons with POD and offered them standard medical management, which included buprenorphine (usually 12 - 16 mg maximum, adjusted for addiction, not pain), an initial 1-hour visit, and weekly 20-minute sessions with a physician who counseled the patients and monitored for drug adverse effects. Half the group remained in this standard medical management (SMM) group and half received enhanced medical management (EMM), which included twice-weekly 60-minute individualized drug counseling focusing on interpersonal issues, coping with triggers and high-risk situations, homework, and so forth.

Under a somewhat complicated schema, patients were evaluated after periods of individualized buprenorphine tapering and maintenance and were assessed for abstinence from opioids at various times.

Study Population

All patients had a Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, diagnosis of opioid dependence and had used opioids for at least 20 of the last 30 days. Other substance abuse disorders were allowed, with the exception of active heroin use or history of injecting heroin. All patients expressed an interest in stopping opioids.

The population was made up of 60% men, was 91% white, had a mean age of 33 years, was likely to be cigarette smokers (71%), and had been using opioids for an average of 4.5 years. Most patients had received some college education and were employed full-time. There were no significant differences at baseline between the SMM and EMM groups.

A number of patients reported current chronic pain (42%), and some were taking opioids for this condition. Although current polypharmacy was uncommon, many patients reported a lifetime history of heroin use (23%), alcohol abuse (60%) or dependence (27%), cannabis abuse (47%) or dependence (15%), and cocaine abuse (32%) or dependence (18%). Stimulant and sedative use were less common.

Opioids used within 30 days included sustained-release oxycodone (35%), hydrocodone (32%), immediate-release oxycodone (19%), methadone (6%), and others (8%).

Thirty percent of subjects had received some previous treatment for opioid dependency, primarily "self help" (59%), inpatient/residential treatment (42%), outpatient counseling (40%), and methadone maintenance (31%).

"For most subjects, this was the first treatment for opioid dependence," said Dr. Weiss.

Treatment and Maintenance

Treatment success was defined as 4 or fewer days of opioid use per month, no positive urine screens for opioids for 2 consecutive weeks, no other formal substance abuse treatment, and no injection of opioids.

Phase 1 included 1 month of tapering and 2 months of stabilization. At the end of this time, few patients were successfully treated, and enhanced management did not influence the results, Dr. Weiss reported.

In the SMM group, only 7% met the criteria for success, as did just 6% of the EMM group (P = .45). "Nearly all patients relapsed after a 4-week taper," Dr. Weiss said.

Patients who relapsed were asked to enter phase 2, at which time 360 patients were again randomly assigned to SMM or EMM and received 3 months of buprenorphine stabilization, then had treatment tapered for 1 month, with a 2-month follow-up.

At the end of the stabilization (at week 12), substantial improvement was noted for 52% of the EMM group and 47% of the SMM group, though again there was no additional benefit to enhanced management (P = .3). Substantial improvement was defined as abstinence for 3 or more of the final 4 weeks of buprenorphine stabilization (urine-confirmed self-report).

However, by the end of the stabilization period, many patients had relapsed again, Dr. Weiss reported.

"We went from an average success rate of 49% to 26% at week 16,"he said. At week 24 (8 weeks posttaper), only 9% of patients remained successfully treated.

"At the end of the study, we were back into phase 1 territory," he said. "Seven of 8 patients doing well on buprenorphine maintenance had relapsed."

Predictors of Outcome

The only predictor outcome was ever-use of heroin. At week 12, improvement was noted for 37% of those reporting lifetime heroin use compared with 54% of those without such a history (P = .003); at week 24, this was 5% and 10%, respectively (P = .13). "Having dabbled in heroin was a bad prognostic sign," Dr. Weiss observed.

The presence of chronic pain did not influence outcomes. Patients with chronic pain were equally likely to enter phase 2 (indicating early treatment failure) and were equally likely to be substantially improved at week 12 of phase 2 (53% vs 47% for those without chronic pain).

Chronic pain tended to be lumbar/sacral (65%) and classified as only moderate (median 4.4 on 10-point scale) but was of long duration, as more than half the patients had suffered from it for at least 4 years, he said.

"Interestingly, we found that in many cases the patient's pain got better," he added. More than half the subjects reported at least a moderate reduction of pain from baseline (≥30%), and one third had a substantial improvement (≥50%).

Nevertheless, Dr. Weiss said one cannot assume that buprenorphine itself improved the pain, as there was no control group, "but it is an intriguing possibility," he commented.

Sean Mackey, MD, PhD, associate professor of anesthesia and chief of the Division of Pain Management at Stanford University, Palo Alto, California, who delivered an overview of the treatment of pain in patients with addiction at the session, commented on the current study for Medscape Psychiatry.

He was particularly interested in the finding that persons with a history of heroin use had worse outcomes. "Could it be that prior exposure to heroin fundamentally alters the neurobiology in this group such that they need higher doses of buprenorphine to prevent relapse?" he asked.

Dr. Mackey maintained that the study is important because it asked a clinically relevant question: "Does putting people on a short period of buprenorphine maintenance combined with counseling lead to reductions in relapse? It's a great idea, and a wonderful hypothesis, because if it does work then this would be a huge win. We would not have to use extended maintenance. Unfortunately, it did not work, but the study needed to be done."

He further noted that the standard management group was likely getting better care in this study than is delivered in usual practice, which may have diluted potential differences.

Dr. Weiss has reported receiving research support from Eli Lilly. Dr. Mackey has disclosed no relevant financial relationships.

American Psychiatric Association 2010 Annual Meeting: Symposium 36, presentation 4. Presented May 23, 2010